{"id":4964,"date":"2013-10-01T09:00:00","date_gmt":"2013-10-01T09:00:00","guid":{"rendered":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/t-cel-gerichte-therapie-bij-type-1-diabetes\/"},"modified":"2024-09-23T11:22:43","modified_gmt":"2024-09-23T11:22:43","slug":"t-cel-gerichte-therapie-bij-type-1-diabetes","status":"publish","type":"post","link":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/t-cel-gerichte-therapie-bij-type-1-diabetes\/","title":{"rendered":"T-cel gerichte therapie bij Type 1 Diabetes"},"content":{"rendered":"<p>Als iemand met Type 1 Diabetes (T1D) wordt gediagnosticeerd, worden de betacellen die insuline maken aangevallen door het eigen lichaam. Ze worden aangevallen door zogeheten T-cellen. Uit eerder gedaan onderzoek blijkt dat een bepaald middel <i>(antithymocyte globulin (ATG))<\/i> dit proces zou kunnen remmen. Dit middel werd daarom getest bij mensen van 12 tot 35 jaar die net met T1D waren gediagnosticeerd.<\/p>\n<p>In totaal kregen 38 net gediagnosticeerde diabeten de ATG therapie. Deze mensen werden vergeleken met 20 mensen met net gediagnosticeerde diabetes die de ATG therapie niet kregen. Na 12 maanden bleek de functie van de b\u00e8tacellen (hoeveel eigen insuline de cellen nog produceren) in beide groepen gelijk. Dit middel is dus niet effectief om het proces te remmen. De resultaten van deze studie werden gepubliceerd in <a href=\"http:\/\/www.thelancet.com\/journals\/landia\/article\/PIIS2213-8587%2813%2970065-2\/abstract\" target=\"_blank\" rel=\"noreferrer noopener\">The Lancet Diabetes &amp; Endocrinology<\/a>. Dit onderzoek werd mede gefinancierd door Breakthrough T1D. <a href=\"http:\/\/medicalxpress.com\/news\/2013-08-t-cell-therapy-diabetes.html\" target=\"_blank\" rel=\"noreferrer noopener\">Lees meer&#8230;<\/a><\/p>\n<p> <\/p>","protected":false,"raw":""},"excerpt":{"rendered":"<p>Als iemand met Type 1 Diabetes (T1D) wordt gediagnosticeerd, worden de betacellen die insuline maken aangevallen door het eigen lichaam. Ze worden aangevallen door zogeheten T-cellen. Uit eerder gedaan onderzoek blijkt dat een bepaald middel (antithymocyte globulin (ATG)) dit proces zou kunnen remmen. Dit middel werd daarom getest bij mensen van 12 tot 35 jaar [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[184,187,188],"tags":[],"class_list":["post-4964","post","type-post","status-publish","format-standard","hentry","category-archief","category-behandelen","category-genezen"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>T-cel gerichte therapie bij Type 1 Diabetes - Breakthrough T1D<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/t-cel-gerichte-therapie-bij-type-1-diabetes\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"T-cel gerichte therapie bij Type 1 Diabetes - Breakthrough T1D\" \/>\n<meta property=\"og:description\" content=\"Als iemand met Type 1 Diabetes (T1D) wordt gediagnosticeerd, worden de betacellen die insuline maken aangevallen door het eigen lichaam. Ze worden aangevallen door zogeheten T-cellen. Uit eerder gedaan onderzoek blijkt dat een bepaald middel (antithymocyte globulin (ATG)) dit proces zou kunnen remmen. Dit middel werd daarom getest bij mensen van 12 tot 35 jaar [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/t-cel-gerichte-therapie-bij-type-1-diabetes\/\" \/>\n<meta property=\"og:site_name\" content=\"Breakthrough T1D\" \/>\n<meta property=\"article:published_time\" content=\"2013-10-01T09:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-23T11:22:43+00:00\" \/>\n<meta name=\"author\" content=\"ylt-admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Geschreven door\" \/>\n\t<meta name=\"twitter:data1\" content=\"ylt-admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Geschatte leestijd\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/t-cel-gerichte-therapie-bij-type-1-diabetes\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/t-cel-gerichte-therapie-bij-type-1-diabetes\/\"},\"author\":{\"name\":\"ylt-admin\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6\"},\"headline\":\"T-cel gerichte therapie bij Type 1 Diabetes\",\"datePublished\":\"2013-10-01T09:00:00+00:00\",\"dateModified\":\"2024-09-23T11:22:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/t-cel-gerichte-therapie-bij-type-1-diabetes\/\"},\"wordCount\":146,\"publisher\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\"},\"articleSection\":[\"Archief\",\"Behandelen\",\"Genezen\"],\"inLanguage\":\"nl-NL\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/t-cel-gerichte-therapie-bij-type-1-diabetes\/\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/t-cel-gerichte-therapie-bij-type-1-diabetes\/\",\"name\":\"T-cel gerichte therapie bij Type 1 Diabetes - Breakthrough T1D\",\"isPartOf\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#website\"},\"datePublished\":\"2013-10-01T09:00:00+00:00\",\"dateModified\":\"2024-09-23T11:22:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/t-cel-gerichte-therapie-bij-type-1-diabetes\/#breadcrumb\"},\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/t-cel-gerichte-therapie-bij-type-1-diabetes\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/t-cel-gerichte-therapie-bij-type-1-diabetes\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/breakthrought1d.eu\/nl\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"T-cel gerichte therapie bij Type 1 Diabetes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#website\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/\",\"name\":\"Breakthrough T1D\",\"description\":\"Wij zetten ons in voor een toekomst zonder T1D\",\"publisher\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/breakthrought1d.eu\/nl\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\",\"name\":\"Breakthrough T1D\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png\",\"contentUrl\":\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png\",\"width\":330,\"height\":141,\"caption\":\"Breakthrough T1D\"},\"image\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6\",\"name\":\"ylt-admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g\",\"caption\":\"ylt-admin\"},\"sameAs\":[\"https:\/\/87.250.144.92\"],\"url\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/author\/ylt-admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"T-cel gerichte therapie bij Type 1 Diabetes - Breakthrough T1D","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/t-cel-gerichte-therapie-bij-type-1-diabetes\/","og_locale":"nl_NL","og_type":"article","og_title":"T-cel gerichte therapie bij Type 1 Diabetes - Breakthrough T1D","og_description":"Als iemand met Type 1 Diabetes (T1D) wordt gediagnosticeerd, worden de betacellen die insuline maken aangevallen door het eigen lichaam. Ze worden aangevallen door zogeheten T-cellen. Uit eerder gedaan onderzoek blijkt dat een bepaald middel (antithymocyte globulin (ATG)) dit proces zou kunnen remmen. Dit middel werd daarom getest bij mensen van 12 tot 35 jaar [&hellip;]","og_url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/t-cel-gerichte-therapie-bij-type-1-diabetes\/","og_site_name":"Breakthrough T1D","article_published_time":"2013-10-01T09:00:00+00:00","article_modified_time":"2024-09-23T11:22:43+00:00","author":"ylt-admin","twitter_card":"summary_large_image","twitter_misc":{"Geschreven door":"ylt-admin","Geschatte leestijd":"1 minuut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/t-cel-gerichte-therapie-bij-type-1-diabetes\/#article","isPartOf":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/t-cel-gerichte-therapie-bij-type-1-diabetes\/"},"author":{"name":"ylt-admin","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6"},"headline":"T-cel gerichte therapie bij Type 1 Diabetes","datePublished":"2013-10-01T09:00:00+00:00","dateModified":"2024-09-23T11:22:43+00:00","mainEntityOfPage":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/t-cel-gerichte-therapie-bij-type-1-diabetes\/"},"wordCount":146,"publisher":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#organization"},"articleSection":["Archief","Behandelen","Genezen"],"inLanguage":"nl-NL"},{"@type":"WebPage","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/t-cel-gerichte-therapie-bij-type-1-diabetes\/","url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/t-cel-gerichte-therapie-bij-type-1-diabetes\/","name":"T-cel gerichte therapie bij Type 1 Diabetes - Breakthrough T1D","isPartOf":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#website"},"datePublished":"2013-10-01T09:00:00+00:00","dateModified":"2024-09-23T11:22:43+00:00","breadcrumb":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/t-cel-gerichte-therapie-bij-type-1-diabetes\/#breadcrumb"},"inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/breakthrought1d.eu\/nl\/nieuws\/t-cel-gerichte-therapie-bij-type-1-diabetes\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/t-cel-gerichte-therapie-bij-type-1-diabetes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/breakthrought1d.eu\/nl\/"},{"@type":"ListItem","position":2,"name":"T-cel gerichte therapie bij Type 1 Diabetes"}]},{"@type":"WebSite","@id":"https:\/\/breakthrought1d.eu\/nl\/#website","url":"https:\/\/breakthrought1d.eu\/nl\/","name":"Breakthrough T1D","description":"Wij zetten ons in voor een toekomst zonder T1D","publisher":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/breakthrought1d.eu\/nl\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"},{"@type":"Organization","@id":"https:\/\/breakthrought1d.eu\/nl\/#organization","name":"Breakthrough T1D","url":"https:\/\/breakthrought1d.eu\/nl\/","logo":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/","url":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png","contentUrl":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png","width":330,"height":141,"caption":"Breakthrough T1D"},"image":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6","name":"ylt-admin","image":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g","caption":"ylt-admin"},"sameAs":["https:\/\/87.250.144.92"],"url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/author\/ylt-admin\/"}]}},"_links":{"self":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/4964","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/comments?post=4964"}],"version-history":[{"count":1,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/4964\/revisions"}],"predecessor-version":[{"id":7239,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/4964\/revisions\/7239"}],"wp:attachment":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/media?parent=4964"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/categories?post=4964"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/tags?post=4964"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}